昆明医科大学学报Issue(1)：56-58,67,4.
失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗
Antivirus Treatment for Patients with Hepatitis C Cirrhosis at Decompensated Stage after Elimination of Complication
摘要
Abstract
Objective To observe the efficacy of antiviral therapy of pegylated interferon (Peg-IFN) α-2a combined with ribavirin for patients with hepatitis C cirrhosis and hypersplenism underwent splenectomy or partial splenic embolization. Methods Thirty-eight patients with hepatitis C cirrhosis (genotype Ⅰ HCV infection) hypersplenism failed to the anti-viral therapy were performed splenectomy or partial splenic embolization to improving hypersplenism. After 3 months,Peg-IFNα-2a 90μg or 135 μg was given subcutaneously once weekly, plus ribavirin 600-1 000 mg/d orally for 1 year of the treatment. During the treatment, patients were followed at four-week intervals, and then followed-up every month until the 24th week after stopping. Liver function, blood routine, renal function, HCV RNA, and adverse reaction of medication were observed during treatment and the follow-up period. Results Splenic function of patients with hepatitis C cirrhosis and hypersplenism was improved after hypersplenism splenectomy or partial splenic embolization. The sustained virologic response (SVR) rate was 63.88%after giving Peg-IFNα-2a combined with ribavirin anti-viral treatment. Conclusion After splenectomy or partial splenic embolization, patients with hepatitis C cirrhosis and hypersplenism showed the better SVR at the treatment of Peg-IFNα-2a combined with ribavirin. The treatment could delay the progress of the hepatitis C cirrhosis and reduce the incidence of liver failure and liver cancer.关键词
丙型/慢性/肝硬化/肝炎/并发症/聚乙二醇干扰素α-2aKey words
Hepatitis C/Chronic/Liver cirrhosis/Hapetitis/Complication/Peg-IFNα-2a分类
医药卫生引用本文复制引用
杨永锐,李晖,沈凌,汪亚玲..失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗[J].昆明医科大学学报,2014,(1):56-58,67,4.基金项目
云南省科技厅科研基金资助项目（2013FZ226）；昆明市卫生局科研基金资助项目 （）
